Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Lifesci Capital

Prime Medicine (NASDAQ:PRME) was upgraded by stock analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research analysts have also weighed in on PRME. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prime Medicine in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Prime Medicine from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Prime Medicine Stock Down 9.2%

Shares of NASDAQ:PRME opened at $4.23 on Monday. The business’s 50-day simple moving average is $3.80. Prime Medicine has a one year low of $1.11 and a one year high of $6.94. The company has a market cap of $763.56 million, a PE ratio of -2.94 and a beta of 2.56.

Prime Medicine (NASDAQ:PRME) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.24) earnings per share for the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%. The company had revenue of $0.84 million during the quarter.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.